Premium
Steroid minimization for sirolimus‐treated renal transplant recipients
Author(s) -
Matas Arthur J.,
Granger Darla,
Kaufman Dixon B.,
Sarwal Minnie M.,
Ferguson Ronald M.,
Woodle E. Steve,
Gill John S.
Publication year - 2011
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2010.01282.x
Subject(s) - sirolimus , medicine , discontinuation , immunosuppression , calcineurin , context (archaeology) , steroid , tacrolimus , renal transplant , kidney transplantation , urology , transplantation , pharmacology , paleontology , hormone , biology
Matas AJ, Granger D, Kaufman DB, Sarwal MM, Ferguson RM, Woodle ES, Gill JS. Steroid minimization for sirolimus‐treated renal transplant recipients.
Clin Transplant 2011: 25: 457–467. © 2010 John Wiley & Sons A/S. Abstract: Steroids are associated with a myriad of post‐transplant side effects. Therefore, as new immunosuppressive drugs have been developed, attempts have been made to minimize steroid exposure. Sirolimus (SRL) has been demonstrated to have efficacy in early and late post‐transplant immunosuppression. Accordingly, numerous trials have studied steroid minimization (early and late post‐transplant) in the context of SRL‐containing protocols (either with or without a calcineurin inhibitor). We herein review these trials and show that recent studies have determined that both late steroid withdrawal and early rapid discontinuation can be successful with SRL immunosuppression.